Cameron Stewart

This study identifies the endothelial protein C receptor (EPCR) as the entry receptor for Langya virus and reveals the molecular basis of its interaction with the viral attachment glycoprotein.

This study determines the structure of the 2026 Bundibugyo virus glycoprotein and identifies conserved epitopes for antibody therapeutics and pan-ebolavirus vaccines.

The paper shows how SARS-CoV-2 variants, particularly Omicron, evolved proteolytic controls at the Spike furin cleavage site to enhance transmission while reducing lower respiratory tract pathogenicity.

This paper computationally designs thermostable miniproteins that neutralize Nipah and Hendra viruses with subnanomolar affinity and potent in vitro antiviral activity.

The paper shows repeated SARS-CoV-2 vaccine boosters elicit variant-specific memory B cells and neutralizing antibodies, suggesting immune imprinting can be overcome with updated vaccines.

The paper examines how mutations in the HCoV-229E spike affect receptor binding and serum neutralization, revealing counterbalancing effects on these functions.

This study measures the functional and antigenic effects of ~8,500 F protein mutations in Nipah virus using pseudoviruses, revealing constraints on its structure and neutralization by antibodies.

This study evaluates linker types for enhancing crystallization of proteins fused to TELSAM, finding that linker choice depends on the target protein's properties.

This study designs miniproteins that inhibit MERS-CoV by targeting the spike protein, showing broad neutralization and protective efficacy in mice.

This study identifies a potent monoclonal antibody, MARV16, that broadly neutralizes Marburg virus and related viruses, with a cryo-EM structure revealing its mechanism of action.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

HKU5 merbecoviruses use bat Pipistrellus abramus ACE2 and several artiodactyl ACE2s through a cryo-EM-defined binding mode distinct from other ACE2-using coronaviruses, showing independent evolution of ACE2 usage.

The paper identifies two European bat MERS-related coronaviruses that use ACE2 as their receptor, revealing a distinct binding mode and host tropism determinants.

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

This study identifies molecular mechanisms of FCoV-23 pathogenicity, including receptor usage and biotype switching, and identifies a cross-reactive antibody for therapeutic development.

This study maps immunodominant sites on MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans, showing peak neutralizing activity against S1 and RBD epitopes.

This study determines the structure of HKU1 spike RBD bound to TMPRSS2, identifies host receptor usage determinants, and shows the role of antibodies and glycan shielding in neutralization.

This study uses deep mutational scanning to assess how mutations in SARS-CoV-2 spike proteins affect ACE2 binding, cell entry, and serum escape, linking these effects to clade growth rates.

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.

This study characterizes the receptor tropism and antigenicity of a clade 3 sarbecovirus, identifying broad ACE2 usage and cross-neutralizing antibodies with implications for vaccine design.